JP2013542194A5 - - Google Patents

Download PDF

Info

Publication number
JP2013542194A5
JP2013542194A5 JP2013530383A JP2013530383A JP2013542194A5 JP 2013542194 A5 JP2013542194 A5 JP 2013542194A5 JP 2013530383 A JP2013530383 A JP 2013530383A JP 2013530383 A JP2013530383 A JP 2013530383A JP 2013542194 A5 JP2013542194 A5 JP 2013542194A5
Authority
JP
Japan
Prior art keywords
seq
antigen
antibody
binding fragment
amino acids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013530383A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013542194A (ja
JP6096117B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/053193 external-priority patent/WO2012047567A1/en
Publication of JP2013542194A publication Critical patent/JP2013542194A/ja
Publication of JP2013542194A5 publication Critical patent/JP2013542194A5/ja
Application granted granted Critical
Publication of JP6096117B2 publication Critical patent/JP6096117B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013530383A 2010-09-27 2011-09-26 抗cd48抗体およびその使用 Expired - Fee Related JP6096117B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US38674610P 2010-09-27 2010-09-27
US61/386,746 2010-09-27
US201161475280P 2011-04-14 2011-04-14
US61/475,280 2011-04-14
US201161515490P 2011-08-05 2011-08-05
US61/515,490 2011-08-05
PCT/US2011/053193 WO2012047567A1 (en) 2010-09-27 2011-09-26 Anti-cd48 antibodies and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016210605A Division JP2017036324A (ja) 2010-09-27 2016-10-27 抗cd48抗体およびその使用

Publications (3)

Publication Number Publication Date
JP2013542194A JP2013542194A (ja) 2013-11-21
JP2013542194A5 true JP2013542194A5 (https=) 2014-11-13
JP6096117B2 JP6096117B2 (ja) 2017-03-15

Family

ID=45870888

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013530383A Expired - Fee Related JP6096117B2 (ja) 2010-09-27 2011-09-26 抗cd48抗体およびその使用
JP2016210605A Pending JP2017036324A (ja) 2010-09-27 2016-10-27 抗cd48抗体およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016210605A Pending JP2017036324A (ja) 2010-09-27 2016-10-27 抗cd48抗体およびその使用

Country Status (19)

Country Link
US (1) US9228014B2 (https=)
EP (1) EP2621952A1 (https=)
JP (2) JP6096117B2 (https=)
KR (1) KR20140014067A (https=)
CN (1) CN103261226B (https=)
AR (1) AR083044A1 (https=)
AU (1) AU2011312623B2 (https=)
BR (1) BR112013007314A2 (https=)
CA (1) CA2812748A1 (https=)
CL (1) CL2013000843A1 (https=)
EA (1) EA030437B1 (https=)
IL (1) IL225484A (https=)
MX (1) MX348417B (https=)
MY (1) MY165273A (https=)
NZ (1) NZ608660A (https=)
PH (1) PH12013500564A1 (https=)
SG (1) SG189089A1 (https=)
TW (1) TWI507416B (https=)
WO (1) WO2012047567A1 (https=)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9533039B2 (en) * 2010-09-27 2017-01-03 Regeneron Pharmaceuticals, Inc. Methods of treating systemic lupus erythematosus (SLE) using anti-CD48 antibodies
LT3578201T (lt) 2012-06-28 2023-05-25 University Of Central Florida Research Foundation Incorporated Nk ląstelių metodai ir kompozicijos
AR095196A1 (es) 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
WO2016036252A2 (en) * 2014-09-05 2016-03-10 Aimm Therapeutics B.V. Hepatitis c virus specific antibody
DK3270965T3 (da) 2015-03-18 2020-06-08 Seattle Genetics Inc Cd48-antistoffer og konjugater deraf
TWI870789B (zh) 2015-08-04 2025-01-21 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
EP3504328A1 (en) 2016-08-24 2019-07-03 Regeneron Pharmaceuticals, Inc. Host cell protein modification
JP6805884B2 (ja) 2017-02-28 2020-12-23 住友ゴム工業株式会社 二輪自動用空気入りタイヤ
BR112020000127A2 (pt) 2017-07-06 2020-07-07 Regeneron Pharmaceuticals, Inc. método para selecionar um hidrolisado de soja, e, glicoproteína
MX2020006639A (es) 2017-12-22 2020-09-14 Regeneron Pharma Sistema y metodo para caracterizar las impurezas de un producto farmaceutico.
BR112020013336A2 (pt) 2018-01-31 2020-12-01 Regeneron Pharmaceuticals, Inc. produto farmacêutico proteico, métodos para caracterizar as impurezas do produto farmacêutico proteico de alto peso molecular intermediário, para produção de um anticorpo, e para caracterizar as impurezas de fármaco com variação de carga, anticorpo, e, sistema para caracterizar impurezas de fármaco de alto peso molecular intermediário.
TW202311746A (zh) 2018-02-02 2023-03-16 美商再生元醫藥公司 用於表徵蛋白質二聚合之系統及方法
WO2019168774A1 (en) 2018-02-28 2019-09-06 Regeneron Pharmaceuticals, Inc. Systems and methods for identifying viral contaminants
US12259355B2 (en) 2018-03-19 2025-03-25 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
US12253490B2 (en) 2018-03-19 2025-03-18 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
HUE065344T2 (hu) 2018-03-19 2024-05-28 Regeneron Pharma Mikrochip kapilláris elektroforézis assay-k és reagensek
TW202016125A (zh) 2018-05-10 2020-05-01 美商再生元醫藥公司 用於定量及調節蛋白質黏度之系統與方法
CN119264211A (zh) 2018-08-27 2025-01-07 瑞泽恩制药公司 拉曼光谱在下游纯化中的应用
JP7511542B2 (ja) 2018-08-30 2024-07-05 リジェネロン・ファーマシューティカルズ・インコーポレイテッド タンパク質複合体を特徴づけるための方法
WO2020150491A1 (en) 2019-01-16 2020-07-23 Regeneron Pharmaceuticals, Inc. Methods for characterizing disulfide bonds
WO2020231992A1 (en) 2019-05-13 2020-11-19 Regeneron Pharmaceuticals, Inc. Improved competitive ligand binding assays
WO2021061790A1 (en) 2019-09-24 2021-04-01 Regeneron Pharmaceuticals, Inc. Systems and methods for chromatography use and regeneration
US12297451B1 (en) 2019-10-25 2025-05-13 Regeneron Pharmaceuticals, Inc. Cell culture medium
CA3158119A1 (en) 2019-11-25 2021-06-03 Regeneron Pharmaceuticals, Inc. Sustained release formulations using non-aqueous emulsions
CN115398236B (zh) 2020-01-21 2024-06-11 瑞泽恩制药公司 用于糖基化的蛋白质的电泳的去糖基化方法
CR20220596A (es) 2020-05-26 2023-01-23 Boehringer Ingelheim Int Anticuerpos anti-pd-1
WO2022047108A1 (en) 2020-08-31 2022-03-03 Regeneron Pharmaceuticals, Inc. Asparagine feed strategies to improve cell culture performance and mitigate asparagine sequence variants
PE20240225A1 (es) 2020-11-24 2024-02-16 Novartis Ag Anticuerpos anti-cd48, conjugados de anticuerpo-farmaco, y usos de los mismos
WO2022115588A1 (en) 2020-11-25 2022-06-02 Regeneron Pharmaceuticals, Inc. Sustained release formulations using non-aqueous membrane emulsification
KR20230121854A (ko) 2020-12-17 2023-08-21 리제너론 파아마슈티컬스, 인크. 단백질-캡슐화 마이크로겔의 제작
MX2023008527A (es) 2021-01-20 2023-07-28 Regeneron Pharma Metodos para mejorar el valor proteico en cultivo celular.
JP2024512299A (ja) 2021-03-03 2024-03-19 リジェネロン・ファーマシューティカルズ・インコーポレイテッド タンパク質の粘度を定量及び変更するためのシステム及び方法
AU2022243005A1 (en) 2021-03-26 2023-10-05 Regeneron Pharmaceuticals, Inc. Methods and systems for developing mixing protocols
BR112023024984A2 (pt) 2021-06-01 2024-02-20 Regeneron Pharma Tampão de amostra de eletroforese aquosa, método para identificar contaminantes ou impurezas em uma amostra de droga proteica, e, kit
US20230077710A1 (en) 2021-09-08 2023-03-16 Regeneron Pharmaceuticals, Inc. HIGH-THROUGHPUT AND MASS-SPECTROMETRY-BASED METHOD FOR QUANTITATING ANTIBODIES AND OTHER Fc-CONTAINING PROTEINS
CA3232463A1 (en) 2021-09-20 2023-03-23 Philip Mellors Methods of controlling antibody heterogeneity
CA3230984A1 (en) 2021-10-07 2023-04-13 Ross BROWNE Systems and methods of ph modeling and control
WO2023059803A1 (en) 2021-10-07 2023-04-13 Regeneron Pharmaceuticals, Inc. Ph meter calibration and correction
TW202330104A (zh) 2021-10-26 2023-08-01 美商再生元醫藥公司 用於產生實驗室用水及分配不同溫度之實驗室用水的系統及方法
KR20240164561A (ko) 2022-03-18 2024-11-19 리제너론 파아마슈티컬스, 인크. 폴리펩타이드 변종을 분석하기 위한 방법 및 시스템
TW202435942A (zh) 2022-12-16 2024-09-16 美商里珍納龍藥品有限公司 評估層析管柱完整性的方法及系統
US20240245779A1 (en) 2023-01-25 2024-07-25 Regeneron Pharmaceuticals, Inc. Methods of modeling liquid protein composition stability
EP4655595A1 (en) 2023-01-25 2025-12-03 Regeneron Pharmaceuticals, Inc. Mass spectrometry-based characterization of antibodies co-expressed in vivo
WO2024163708A1 (en) 2023-02-01 2024-08-08 Regeneron Pharmaceuticals, Inc. Asymmetrical flow field-flow fractionation with mass spectrometry for biomacromolecule analysis
EP4669963A2 (en) 2023-02-22 2025-12-31 Regeneron Pharmaceuticals, Inc. SYSTEM FITNESS PARAMETERS AND COLUMN AGING
KR20240147948A (ko) * 2023-03-29 2024-10-10 웰마커바이오 주식회사 Igsf1 특이적 결합 단백질 및 이의 용도
US20240366471A1 (en) 2023-05-01 2024-11-07 Regeneron Pharmaceuticals, Inc. Multidose antibody drug products using phenol or benzyl alcohol
WO2025054406A1 (en) 2023-09-08 2025-03-13 Regeneron Pharmaceuticals, Inc. Methods and systems for assessing chromatographic column integrity
US20250095773A1 (en) 2023-09-18 2025-03-20 Regeneron Pharmaceuticals, Inc. Methods and systems for developing chromatography protocols
US20250109905A1 (en) 2023-09-29 2025-04-03 Regeneron Pharmaceuticals, Inc. Lyophilization using controlled nucleation
US20250129117A1 (en) 2023-10-18 2025-04-24 Regeneron Pharmaceuticals, Inc. Rapid purification of monoclonal antibody from in-process upstream cell culture material
US20250145662A1 (en) 2023-11-02 2025-05-08 Regeneron Pharmaceuticals, Inc. Methods for reducing lipase activity using stress
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
WO2025166281A1 (en) 2024-02-01 2025-08-07 Regeneron Pharmaceuticals, Inc. Platform for charge-detection mass spectrometry analysis of aavs
WO2025175164A1 (en) 2024-02-16 2025-08-21 Regeneron Pharmaceuticals, Inc. Methods of producing concentrated formulated drug substances comprising proteins, and concentrated formulated drug substance made by the methods
TW202602489A (zh) 2024-03-15 2026-01-16 美商再生元醫藥公司 作為經穩定的蛋白質調配物之賦形劑的聚山梨醇酯及聚氧乙烯山梨糖醇酐
WO2025259840A1 (en) 2024-06-13 2025-12-18 Regeneron Pharmaceuticals, Inc. Methods and systems for scaled chromatography
WO2026025028A1 (en) 2024-07-26 2026-01-29 Regeneron Pharmaceuticals, Inc. Methods of making ultra-high concentrated protein formulations using lyophilization
WO2026060350A1 (en) 2024-09-13 2026-03-19 Regeneron Pharmaceuticals, Inc. Methods of improving photo stability and controlling formation of hmw species in biologic formulations, and biologic formulations produced by the methods
WO2026076201A2 (en) 2024-10-03 2026-04-09 Regeneron Pharmaceuticals, Inc. Systems and methods for producing therapeutic proteins using single pass tangential flow filtration for in-line concentration and volume reduction of production pools
WO2026080597A1 (en) 2024-10-08 2026-04-16 Regeneron Pharmaceuticals, Inc. Sustained delivery of biologics and non-aqueous manufacture of same

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4692405A (en) 1985-03-05 1987-09-08 Dana-Farber Cancer Institute, Inc. Monoclonal antibodies to antigen on activated human B-cells and assay therefor, protein antigenic determinant therefor and method of making same
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
US5576423A (en) 1994-12-02 1996-11-19 Schering Corporation Antibodies to the slam protein expressed on activated T cells
WO1997035614A1 (en) 1996-03-27 1997-10-02 Crc For Biopharmaceutical Research Pty. Ltd. The use of antibodies against cd48 for the treatment of t and b cell lymphomas and leukemias
EP1749538A4 (en) 2004-03-31 2009-11-11 Kirin Pharma Kk METHOD FOR DETERMINING THE DIFFERENTIATION OF REGULATORY T CELLS AND THEIR PROLIFERATION WITH GPI ANCHOR PROTEIN AGONISTS AND MEDICINAL COMPOSITION THEREFOR
US7850962B2 (en) 2004-04-20 2010-12-14 Genmab A/S Human monoclonal antibodies against CD20
US8409565B2 (en) * 2006-02-14 2013-04-02 Francesca Levi-Schaffer Therapeutic target and diagnostic marker for asthma and related conditions
JP5307708B2 (ja) 2006-06-02 2013-10-02 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒトil−6受容体に対する高親和性抗体
EP2418222B1 (en) 2009-04-10 2016-11-02 Osaka University Therapeutic agent for treating diseases in which neoplastic proliferation of plasma cells occurs

Similar Documents

Publication Publication Date Title
JP2013542194A5 (https=)
JP2015514110A5 (https=)
NZ610294A (en) Human antibodies to human tnf-like ligand 1a (tl1a)
HRP20171992T1 (hr) Protutijela protiv cgrp
JP2021527431A5 (https=)
JP2015535828A5 (https=)
JP2012523417A5 (https=)
ME02798B (me) Protutijela protiv dkk-1"
JP2014512809A5 (https=)
NZ600768A (en) Human antibodies to human angiopoietin-like protein 4
RU2018119165A (ru) Антитело против лиганда 1 запрограммированной гибели клеток (pd-l1), его антигенсвязывающий фрагмент и их медицинское применение
HRP20160151T1 (hr) PROTUTIJELA PROTIV N3pGlu-AMILOIDNOG BETA PEPTIDA I NJIHOVA UPOTREBA
JP2013542191A5 (https=)
NZ628943A (en) Human antibodies to clostridium difficile toxins
RU2014148502A (ru) Человеческие антитела к fel d1 и способы их применения
RU2010107175A (ru) Антитела человека к cd20 человека и способ их использования
JP2014526898A5 (https=)
RU2020124153A (ru) Гуманизированные антитела к cd19 человека и способы их применения
RU2013145243A (ru) Гуманизированные антитела к ctla4
RU2017137496A (ru) Средство для лечения множественной миеломы (ММ)
RU2018110064A (ru) Антитела к бета-амилоиду
RU2015110981A (ru) Комбинации и их применение
AR098663A1 (es) Anticuerpos multifuncionales que se unen a egfr y met
RU2019104980A (ru) Анти-icos антитела
RU2019139093A (ru) Фармацевтическая композиция на основе антитела к pd-l1 и ее применение